

Global Dendritic Cell Cancer Vaccine Immunotherapy Market Insights, Forecast to 2029

<https://marketpublishers.com/r/GB6C5AE88D16EN.html>

Date: December 2023

Pages: 112

Price: US\$ 4,900.00 (Single User License)

ID: GB6C5AE88D16EN

Abstracts

This report presents an overview of global market for Dendritic Cell Cancer Vaccine Immunotherapy market size. Analyses of the global market trends, with historic market revenue data for 2018 - 2022, estimates for 2023, and projections of CAGR through 2029.

This report researches the key producers of Dendritic Cell Cancer Vaccine Immunotherapy, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Dendritic Cell Cancer Vaccine Immunotherapy, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Dendritic Cell Cancer Vaccine Immunotherapy revenue, market share and industry ranking of main companies, data from 2018 to 2023. Identification of the major stakeholders in the global Dendritic Cell Cancer Vaccine Immunotherapy market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by type and by application, revenue, and growth rate, from 2018 to 2029. Evaluation and forecast the market size for Dendritic Cell Cancer Vaccine Immunotherapy revenue, projected growth trends, production technology, application and end-user industry.

Descriptive company profiles of the major global players, including Lineage Cell Therapeutics, AVAX Technologies, DCPrime, Gradalis, Heat Biologics, ImmunoCellular Therapeutics, Immunicum, MolecuVax and Northwest Biotherapeutics, etc.

By Company

Lineage Cell Therapeutics

AVAX Technologies

DCPrime

Gradalis

Heat Biologics

ImmunoCellular Therapeutics

Immunicum

MolecuVax

Northwest Biotherapeutics

Pique Therapeutics

Regeneus

Tessa Therapeutics

Vaccinogen

XEME Biopharma

Segment by Type

Provenge

Apceden

CreaVax

Others

Segment by Application

Pediatrics

Adults

By Region

North America

United States

Canada

Europe

Germany

France

UK

Italy

Russia

Nordic Countries

Rest of Europe

Asia-Pacific

China

Japan

South Korea

Southeast Asia

India

Australia

Rest of Asia

Latin America

Mexico

Brazil

Rest of Latin America

Middle East, Africa, and Latin America

Turkey

Saudi Arabia

UAE

Rest of MEA

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of

the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Revenue of Dendritic Cell Cancer Vaccine Immunotherapy in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Dendritic Cell Cancer Vaccine Immunotherapy companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: North America by type, by application and by country, revenue for each segment.

Chapter 7: Europe by type, by application and by country, revenue for each segment.

Chapter 8: China by type and by application revenue for each segment.

Chapter 9: Asia (excluding China) by type, by application and by region, revenue for each segment.

Chapter 10: Middle East, Africa, and Latin America by type, by application and by country, revenue for each segment.

Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Dendritic Cell Cancer Vaccine Immunotherapy revenue, gross margin,

and recent development, etc.

Chapter 12: Analyst's Viewpoints/Conclusions

Contents

1 REPORT OVERVIEW

- 1.1 Study Scope
- 1.2 Market Analysis by Type
 - 1.2.1 Global Dendritic Cell Cancer Vaccine Immunotherapy Market Size Growth Rate by Type, 2018 VS 2022 VS 2029
 - 1.2.2 Provenge
 - 1.2.3 Apceden
 - 1.2.4 CreaVax
 - 1.2.5 Others
- 1.3 Market by Application
 - 1.3.1 Global Dendritic Cell Cancer Vaccine Immunotherapy Market Size Growth Rate by Application, 2018 VS 2022 VS 2029
 - 1.3.2 Pediatrics
 - 1.3.3 Adults
- 1.4 Assumptions and Limitations
- 1.5 Study Objectives
- 1.6 Years Considered

2 GLOBAL GROWTH TRENDS

- 2.1 Global Dendritic Cell Cancer Vaccine Immunotherapy Market Perspective (2018-2029)
- 2.2 Global Dendritic Cell Cancer Vaccine Immunotherapy Growth Trends by Region
 - 2.2.1 Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Region: 2018 VS 2022 VS 2029
 - 2.2.2 Dendritic Cell Cancer Vaccine Immunotherapy Historic Market Size by Region (2018-2023)
 - 2.2.3 Dendritic Cell Cancer Vaccine Immunotherapy Forecasted Market Size by Region (2024-2029)
- 2.3 Dendritic Cell Cancer Vaccine Immunotherapy Market Dynamics
 - 2.3.1 Dendritic Cell Cancer Vaccine Immunotherapy Industry Trends
 - 2.3.2 Dendritic Cell Cancer Vaccine Immunotherapy Market Drivers
 - 2.3.3 Dendritic Cell Cancer Vaccine Immunotherapy Market Challenges
 - 2.3.4 Dendritic Cell Cancer Vaccine Immunotherapy Market Restraints

3 COMPETITION LANDSCAPE BY KEY PLAYERS

3.1 Global Revenue Dendritic Cell Cancer Vaccine Immunotherapy by Players

3.1.1 Global Dendritic Cell Cancer Vaccine Immunotherapy Revenue by Players (2018-2023)

3.1.2 Global Dendritic Cell Cancer Vaccine Immunotherapy Revenue Market Share by Players (2018-2023)

3.2 Global Dendritic Cell Cancer Vaccine Immunotherapy Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Global Key Players of Dendritic Cell Cancer Vaccine Immunotherapy, Ranking by Revenue, 2021 VS 2022 VS 2023

3.4 Global Dendritic Cell Cancer Vaccine Immunotherapy Market Concentration Ratio
3.4.1 Global Dendritic Cell Cancer Vaccine Immunotherapy Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Dendritic Cell Cancer Vaccine Immunotherapy Revenue in 2022

3.5 Global Key Players of Dendritic Cell Cancer Vaccine Immunotherapy Head office and Area Served

3.6 Global Key Players of Dendritic Cell Cancer Vaccine Immunotherapy, Product and Application

3.7 Global Key Players of Dendritic Cell Cancer Vaccine Immunotherapy, Date of Enter into This Industry

3.8 Mergers & Acquisitions, Expansion Plans

4 DENDRITIC CELL CANCER VACCINE IMMUNOTHERAPY BREAKDOWN DATA BY TYPE

4.1 Global Dendritic Cell Cancer Vaccine Immunotherapy Historic Market Size by Type (2018-2023)

4.2 Global Dendritic Cell Cancer Vaccine Immunotherapy Forecasted Market Size by Type (2024-2029)

5 DENDRITIC CELL CANCER VACCINE IMMUNOTHERAPY BREAKDOWN DATA BY APPLICATION

5.1 Global Dendritic Cell Cancer Vaccine Immunotherapy Historic Market Size by Application (2018-2023)

5.2 Global Dendritic Cell Cancer Vaccine Immunotherapy Forecasted Market Size by Application (2024-2029)

6 NORTH AMERICA

6.1 North America Dendritic Cell Cancer Vaccine Immunotherapy Market Size (2018-2029)

6.2 North America Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Type

6.2.1 North America Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Type (2018-2023)

6.2.2 North America Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Type (2024-2029)

6.2.3 North America Dendritic Cell Cancer Vaccine Immunotherapy Market Share by Type (2018-2029)

6.3 North America Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Application

6.3.1 North America Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Application (2018-2023)

6.3.2 North America Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Application (2024-2029)

6.3.3 North America Dendritic Cell Cancer Vaccine Immunotherapy Market Share by Application (2018-2029)

6.4 North America Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Country

6.4.1 North America Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Country: 2018 VS 2022 VS 2029

6.4.2 North America Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Country (2018-2023)

6.4.3 North America Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Country (2024-2029)

6.4.4 United States

6.4.5 Canada

7 EUROPE

7.1 Europe Dendritic Cell Cancer Vaccine Immunotherapy Market Size (2018-2029)

7.2 Europe Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Type

7.2.1 Europe Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Type (2018-2023)

7.2.2 Europe Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Type (2024-2029)

7.2.3 Europe Dendritic Cell Cancer Vaccine Immunotherapy Market Share by Type

(2018-2029)

7.3 Europe Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Application

7.3.1 Europe Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Application (2018-2023)

7.3.2 Europe Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Application (2024-2029)

7.3.3 Europe Dendritic Cell Cancer Vaccine Immunotherapy Market Share by Application (2018-2029)

7.4 Europe Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Country

7.4.1 Europe Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Country: 2018 VS 2022 VS 2029

7.4.2 Europe Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Country (2018-2023)

7.4.3 Europe Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Country (2024-2029)

7.4.3 Germany

7.4.4 France

7.4.5 U.K.

7.4.6 Italy

7.4.7 Russia

7.4.8 Nordic Countries

8 CHINA

8.1 China Dendritic Cell Cancer Vaccine Immunotherapy Market Size (2018-2029)

8.2 China Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Type

8.2.1 China Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Type (2018-2023)

8.2.2 China Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Type (2024-2029)

8.2.3 China Dendritic Cell Cancer Vaccine Immunotherapy Market Share by Type (2018-2029)

8.3 China Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Application

8.3.1 China Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Application (2018-2023)

8.3.2 China Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Application (2024-2029)

8.3.3 China Dendritic Cell Cancer Vaccine Immunotherapy Market Share by Application (2018-2029)

9 ASIA (EXCLUDING CHINA)

9.1 Asia Dendritic Cell Cancer Vaccine Immunotherapy Market Size (2018-2029)

9.2 Asia Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Type

9.2.1 Asia Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Type (2018-2023)

9.2.2 Asia Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Type (2024-2029)

9.2.3 Asia Dendritic Cell Cancer Vaccine Immunotherapy Market Share by Type (2018-2029)

9.3 Asia Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Application

9.3.1 Asia Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Application (2018-2023)

9.3.2 Asia Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Application (2024-2029)

9.3.3 Asia Dendritic Cell Cancer Vaccine Immunotherapy Market Share by Application (2018-2029)

9.4 Asia Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Region

9.4.1 Asia Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Region: 2018 VS 2022 VS 2029

9.4.2 Asia Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Region (2018-2023)

9.4.3 Asia Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Region (2024-2029)

9.4.4 Japan

9.4.5 South Korea

9.4.6 China Taiwan

9.4.7 Southeast Asia

9.4.8 India

9.4.9 Australia

10 MIDDLE EAST, AFRICA, AND LATIN AMERICA

10.1 Middle East, Africa, and Latin America Dendritic Cell Cancer Vaccine Immunotherapy Market Size (2018-2029)

10.2 Middle East, Africa, and Latin America Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Type

10.2.1 Middle East, Africa, and Latin America Dendritic Cell Cancer Vaccine

Immunotherapy Market Size by Type (2018-2023)

10.2.2 Middle East, Africa, and Latin America Dendritic Cell Cancer Vaccine

Immunotherapy Market Size by Type (2024-2029)

10.2.3 Middle East, Africa, and Latin America Dendritic Cell Cancer Vaccine

Immunotherapy Market Share by Type (2018-2029)

10.3 Middle East, Africa, and Latin America Dendritic Cell Cancer Vaccine

Immunotherapy Market Size by Application

10.3.1 Middle East, Africa, and Latin America Dendritic Cell Cancer Vaccine

Immunotherapy Market Size by Application (2018-2023)

10.3.2 Middle East, Africa, and Latin America Dendritic Cell Cancer Vaccine

Immunotherapy Market Size by Application (2024-2029)

10.3.3 Middle East, Africa, and Latin America Dendritic Cell Cancer Vaccine

Immunotherapy Market Share by Application (2018-2029)

10.4 Middle East, Africa, and Latin America Dendritic Cell Cancer Vaccine

Immunotherapy Market Size by Country

10.4.1 Middle East, Africa, and Latin America Dendritic Cell Cancer Vaccine

Immunotherapy Market Size by Country: 2018 VS 2022 VS 2029

10.4.2 Middle East, Africa, and Latin America Dendritic Cell Cancer Vaccine

Immunotherapy Market Size by Country (2018-2023)

10.4.3 Middle East, Africa, and Latin America Dendritic Cell Cancer Vaccine

Immunotherapy Market Size by Country (2024-2029)

10.4.4 Brazil

10.4.5 Mexico

10.4.6 Turkey

10.4.7 Saudi Arabia

10.4.8 Israel

10.4.9 GCC Countries

11 KEY PLAYERS PROFILES

11.1 Lineage Cell Therapeutics

11.1.1 Lineage Cell Therapeutics Company Details

11.1.2 Lineage Cell Therapeutics Business Overview

11.1.3 Lineage Cell Therapeutics Dendritic Cell Cancer Vaccine Immunotherapy Introduction

11.1.4 Lineage Cell Therapeutics Revenue in Dendritic Cell Cancer Vaccine Immunotherapy Business (2018-2023)

11.1.5 Lineage Cell Therapeutics Recent Developments

11.2 AVAX Technologies

- 11.2.1 AVAX Technologies Company Details
- 11.2.2 AVAX Technologies Business Overview
- 11.2.3 AVAX Technologies Dendritic Cell Cancer Vaccine Immunotherapy Introduction
- 11.2.4 AVAX Technologies Revenue in Dendritic Cell Cancer Vaccine Immunotherapy Business (2018-2023)
- 11.2.5 AVAX Technologies Recent Developments
- 11.3 DCPrime
 - 11.3.1 DCPrime Company Details
 - 11.3.2 DCPrime Business Overview
 - 11.3.3 DCPrime Dendritic Cell Cancer Vaccine Immunotherapy Introduction
 - 11.3.4 DCPrime Revenue in Dendritic Cell Cancer Vaccine Immunotherapy Business (2018-2023)
 - 11.3.5 DCPrime Recent Developments
- 11.4 Gradalis
 - 11.4.1 Gradalis Company Details
 - 11.4.2 Gradalis Business Overview
 - 11.4.3 Gradalis Dendritic Cell Cancer Vaccine Immunotherapy Introduction
 - 11.4.4 Gradalis Revenue in Dendritic Cell Cancer Vaccine Immunotherapy Business (2018-2023)
 - 11.4.5 Gradalis Recent Developments
- 11.5 Heat Biologics
 - 11.5.1 Heat Biologics Company Details
 - 11.5.2 Heat Biologics Business Overview
 - 11.5.3 Heat Biologics Dendritic Cell Cancer Vaccine Immunotherapy Introduction
 - 11.5.4 Heat Biologics Revenue in Dendritic Cell Cancer Vaccine Immunotherapy Business (2018-2023)
 - 11.5.5 Heat Biologics Recent Developments
- 11.6 ImmunoCellular Therapeutics
 - 11.6.1 ImmunoCellular Therapeutics Company Details
 - 11.6.2 ImmunoCellular Therapeutics Business Overview
 - 11.6.3 ImmunoCellular Therapeutics Dendritic Cell Cancer Vaccine Immunotherapy Introduction
 - 11.6.4 ImmunoCellular Therapeutics Revenue in Dendritic Cell Cancer Vaccine Immunotherapy Business (2018-2023)
 - 11.6.5 ImmunoCellular Therapeutics Recent Developments
- 11.7 Immunicum
 - 11.7.1 Immunicum Company Details
 - 11.7.2 Immunicum Business Overview
 - 11.7.3 Immunicum Dendritic Cell Cancer Vaccine Immunotherapy Introduction

- 11.7.4 Immunicum Revenue in Dendritic Cell Cancer Vaccine Immunotherapy Business (2018-2023)
- 11.7.5 Immunicum Recent Developments
- 11.8 MolecuVax
 - 11.8.1 MolecuVax Company Details
 - 11.8.2 MolecuVax Business Overview
 - 11.8.3 MolecuVax Dendritic Cell Cancer Vaccine Immunotherapy Introduction
 - 11.8.4 MolecuVax Revenue in Dendritic Cell Cancer Vaccine Immunotherapy Business (2018-2023)
 - 11.8.5 MolecuVax Recent Developments
- 11.9 Northwest Biotherapeutics
 - 11.9.1 Northwest Biotherapeutics Company Details
 - 11.9.2 Northwest Biotherapeutics Business Overview
 - 11.9.3 Northwest Biotherapeutics Dendritic Cell Cancer Vaccine Immunotherapy Introduction
 - 11.9.4 Northwest Biotherapeutics Revenue in Dendritic Cell Cancer Vaccine Immunotherapy Business (2018-2023)
 - 11.9.5 Northwest Biotherapeutics Recent Developments
- 11.10 Pique Therapeutics
 - 11.10.1 Pique Therapeutics Company Details
 - 11.10.2 Pique Therapeutics Business Overview
 - 11.10.3 Pique Therapeutics Dendritic Cell Cancer Vaccine Immunotherapy Introduction
 - 11.10.4 Pique Therapeutics Revenue in Dendritic Cell Cancer Vaccine Immunotherapy Business (2018-2023)
 - 11.10.5 Pique Therapeutics Recent Developments
- 11.11 Regeneus
 - 11.11.1 Regeneus Company Details
 - 11.11.2 Regeneus Business Overview
 - 11.11.3 Regeneus Dendritic Cell Cancer Vaccine Immunotherapy Introduction
 - 11.11.4 Regeneus Revenue in Dendritic Cell Cancer Vaccine Immunotherapy Business (2018-2023)
 - 11.11.5 Regeneus Recent Developments
- 11.12 Tessa Therapeutics
 - 11.12.1 Tessa Therapeutics Company Details
 - 11.12.2 Tessa Therapeutics Business Overview
 - 11.12.3 Tessa Therapeutics Dendritic Cell Cancer Vaccine Immunotherapy Introduction
 - 11.12.4 Tessa Therapeutics Revenue in Dendritic Cell Cancer Vaccine

Immunotherapy Business (2018-2023)

11.12.5 Tessa Therapeutics Recent Developments

11.13 Vaccinogen

11.13.1 Vaccinogen Company Details

11.13.2 Vaccinogen Business Overview

11.13.3 Vaccinogen Dendritic Cell Cancer Vaccine Immunotherapy Introduction

11.13.4 Vaccinogen Revenue in Dendritic Cell Cancer Vaccine Immunotherapy

Business (2018-2023)

11.13.5 Vaccinogen Recent Developments

11.14 XEME Biopharma

11.14.1 XEME Biopharma Company Details

11.14.2 XEME Biopharma Business Overview

11.14.3 XEME Biopharma Dendritic Cell Cancer Vaccine Immunotherapy Introduction

11.14.4 XEME Biopharma Revenue in Dendritic Cell Cancer Vaccine Immunotherapy

Business (2018-2023)

11.14.5 XEME Biopharma Recent Developments

12 ANALYST'S VIEWPOINTS/CONCLUSIONS

13 APPENDIX

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.2 Data Source

13.2 Disclaimer

13.3 Author Details

List Of Tables

LIST OF TABLES

Table 1. Global Dendritic Cell Cancer Vaccine Immunotherapy Market Size Growth Rate by Type (US\$ Million), 2018 VS 2022 VS 2029

Table 2. Key Players of Provenge

Table 3. Key Players of Apceden

Table 4. Key Players of CreaVax

Table 5. Key Players of Others

Table 6. Global Dendritic Cell Cancer Vaccine Immunotherapy Market Size Growth Rate by Application (US\$ Million), 2018 VS 2022 VS 2029

Table 7. Global Dendritic Cell Cancer Vaccine Immunotherapy Market Size Growth Rate (CAGR) by Region (US\$ Million): 2018 VS 2022 VS 2029

Table 8. Global Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Region (2018-2023) & (US\$ Million)

Table 9. Global Dendritic Cell Cancer Vaccine Immunotherapy Market Share by Region (2018-2023)

Table 10. Global Dendritic Cell Cancer Vaccine Immunotherapy Forecasted Market Size by Region (2024-2029) & (US\$ Million)

Table 11. Global Dendritic Cell Cancer Vaccine Immunotherapy Market Share by Region (2024-2029)

Table 12. Dendritic Cell Cancer Vaccine Immunotherapy Market Trends

Table 13. Dendritic Cell Cancer Vaccine Immunotherapy Market Drivers

Table 14. Dendritic Cell Cancer Vaccine Immunotherapy Market Challenges

Table 15. Dendritic Cell Cancer Vaccine Immunotherapy Market Restraints

Table 16. Global Dendritic Cell Cancer Vaccine Immunotherapy Revenue by Players (2018-2023) & (US\$ Million)

Table 17. Global Dendritic Cell Cancer Vaccine Immunotherapy Revenue Share by Players (2018-2023)

Table 18. Global Top Dendritic Cell Cancer Vaccine Immunotherapy by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Dendritic Cell Cancer Vaccine Immunotherapy as of 2022)

Table 19. Global Dendritic Cell Cancer Vaccine Immunotherapy Industry Ranking 2021 VS 2022 VS 2023

Table 20. Global 5 Largest Players Market Share by Dendritic Cell Cancer Vaccine Immunotherapy Revenue (CR5 and HHI) & (2018-2023)

Table 21. Global Key Players of Dendritic Cell Cancer Vaccine Immunotherapy, Headquarters and Area Served

Table 22. Global Key Players of Dendritic Cell Cancer Vaccine Immunotherapy, Product and Application

Table 23. Global Key Players of Dendritic Cell Cancer Vaccine Immunotherapy, Product and Application

Table 24. Mergers & Acquisitions, Expansion Plans

Table 25. Global Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Type (2018-2023) & (US\$ Million)

Table 26. Global Dendritic Cell Cancer Vaccine Immunotherapy Revenue Market Share by Type (2018-2023)

Table 27. Global Dendritic Cell Cancer Vaccine Immunotherapy Forecasted Market Size by Type (2024-2029) & (US\$ Million)

Table 28. Global Dendritic Cell Cancer Vaccine Immunotherapy Revenue Market Share by Type (2024-2029)

Table 29. Global Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Application (2018-2023) & (US\$ Million)

Table 30. Global Dendritic Cell Cancer Vaccine Immunotherapy Revenue Share by Application (2018-2023)

Table 31. Global Dendritic Cell Cancer Vaccine Immunotherapy Forecasted Market Size by Application (2024-2029) & (US\$ Million)

Table 32. Global Dendritic Cell Cancer Vaccine Immunotherapy Revenue Share by Application (2024-2029)

Table 33. North America Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Type (2018-2023) & (US\$ Million)

Table 34. North America Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Type (2024-2029) & (US\$ Million)

Table 35. North America Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Application (2018-2023) & (US\$ Million)

Table 36. North America Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Application (2024-2029) & (US\$ Million)

Table 37. North America Dendritic Cell Cancer Vaccine Immunotherapy Growth Rate (CAGR) by Country (US\$ Million): 2018 VS 2022 VS 2029

Table 38. North America Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Country (2018-2023) & (US\$ Million)

Table 39. North America Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Country (2024-2029) & (US\$ Million)

Table 40. Europe Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Type (2018-2023) & (US\$ Million)

Table 41. Europe Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Type (2024-2029) & (US\$ Million)

Table 42. Europe Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Application (2018-2023) & (US\$ Million)

Table 43. Europe Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Application (2024-2029) & (US\$ Million)

Table 44. Europe Dendritic Cell Cancer Vaccine Immunotherapy Growth Rate (CAGR) by Country (US\$ Million): 2018 VS 2022 VS 2029

Table 45. Europe Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Country (2018-2023) & (US\$ Million)

Table 46. Europe Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Country (2024-2029) & (US\$ Million)

Table 47. China Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Type (2018-2023) & (US\$ Million)

Table 48. China Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Type (2024-2029) & (US\$ Million)

Table 49. China Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Application (2018-2023) & (US\$ Million)

Table 50. China Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Application (2024-2029) & (US\$ Million)

Table 51. Asia Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Type (2018-2023) & (US\$ Million)

Table 52. Asia Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Type (2024-2029) & (US\$ Million)

Table 53. Asia Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Application (2018-2023) & (US\$ Million)

Table 54. Asia Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Application (2024-2029) & (US\$ Million)

Table 55. Asia Dendritic Cell Cancer Vaccine Immunotherapy Growth Rate (CAGR) by Region (US\$ Million): 2018 VS 2022 VS 2029

Table 56. Asia Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Region (2018-2023) & (US\$ Million)

Table 57. Asia Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Region (2024-2029) & (US\$ Million)

Table 58. Middle East, Africa, and Latin America Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Type (2018-2023) & (US\$ Million)

Table 59. Middle East, Africa, and Latin America Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Type (2024-2029) & (US\$ Million)

Table 60. Middle East, Africa, and Latin America Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Application (2018-2023) & (US\$ Million)

Table 61. Middle East, Africa, and Latin America Dendritic Cell Cancer Vaccine

Immunotherapy Market Size by Application (2024-2029) & (US\$ Million)

Table 62. Middle East, Africa, and Latin America Dendritic Cell Cancer Vaccine

Immunotherapy Growth Rate (CAGR) by Country (US\$ Million): 2018 VS 2022 VS 2029

Table 63. Middle East, Africa, and Latin America Dendritic Cell Cancer Vaccine

Immunotherapy Market Size by Country (2018-2023) & (US\$ Million)

Table 64. Middle East, Africa, and Latin America Dendritic Cell Cancer Vaccine

Immunotherapy Market Size by Country (2024-2029) & (US\$ Million)

Table 65. Lineage Cell Therapeutics Company Details

Table 66. Lineage Cell Therapeutics Business Overview

Table 67. Lineage Cell Therapeutics Dendritic Cell Cancer Vaccine Immunotherapy Product

Table 68. Lineage Cell Therapeutics Revenue in Dendritic Cell Cancer Vaccine Immunotherapy Business (2018-2023) & (US\$ Million)

Table 69. Lineage Cell Therapeutics Recent Developments

Table 70. AVAX Technologies Company Details

Table 71. AVAX Technologies Business Overview

Table 72. AVAX Technologies Dendritic Cell Cancer Vaccine Immunotherapy Product

Table 73. AVAX Technologies Revenue in Dendritic Cell Cancer Vaccine Immunotherapy Business (2018-2023) & (US\$ Million)

Table 74. AVAX Technologies Recent Developments

Table 75. DCPrime Company Details

Table 76. DCPrime Business Overview

Table 77. DCPrime Dendritic Cell Cancer Vaccine Immunotherapy Product

Table 78. DCPrime Revenue in Dendritic Cell Cancer Vaccine Immunotherapy Business (2018-2023) & (US\$ Million)

Table 79. DCPrime Recent Developments

Table 80. Gradalis Company Details

Table 81. Gradalis Business Overview

Table 82. Gradalis Dendritic Cell Cancer Vaccine Immunotherapy Product

Table 83. Gradalis Revenue in Dendritic Cell Cancer Vaccine Immunotherapy Business (2018-2023) & (US\$ Million)

Table 84. Gradalis Recent Developments

Table 85. Heat Biologics Company Details

Table 86. Heat Biologics Business Overview

Table 87. Heat Biologics Dendritic Cell Cancer Vaccine Immunotherapy Product

Table 88. Heat Biologics Revenue in Dendritic Cell Cancer Vaccine Immunotherapy Business (2018-2023) & (US\$ Million)

Table 89. Heat Biologics Recent Developments

Table 90. ImmunoCellular Therapeutics Company Details

- Table 91. ImmunoCellular Therapeutics Business Overview
- Table 92. ImmunoCellular Therapeutics Dendritic Cell Cancer Vaccine Immunotherapy Product
- Table 93. ImmunoCellular Therapeutics Revenue in Dendritic Cell Cancer Vaccine Immunotherapy Business (2018-2023) & (US\$ Million)
- Table 94. ImmunoCellular Therapeutics Recent Developments
- Table 95. Immunicum Company Details
- Table 96. Immunicum Business Overview
- Table 97. Immunicum Dendritic Cell Cancer Vaccine Immunotherapy Product
- Table 98. Immunicum Revenue in Dendritic Cell Cancer Vaccine Immunotherapy Business (2018-2023) & (US\$ Million)
- Table 99. Immunicum Recent Developments
- Table 100. MolecuVax Company Details
- Table 101. MolecuVax Business Overview
- Table 102. MolecuVax Dendritic Cell Cancer Vaccine Immunotherapy Product
- Table 103. MolecuVax Revenue in Dendritic Cell Cancer Vaccine Immunotherapy Business (2018-2023) & (US\$ Million)
- Table 104. MolecuVax Recent Developments
- Table 105. Northwest Biotherapeutics Company Details
- Table 106. Northwest Biotherapeutics Business Overview
- Table 107. Northwest Biotherapeutics Dendritic Cell Cancer Vaccine Immunotherapy Product
- Table 108. Northwest Biotherapeutics Revenue in Dendritic Cell Cancer Vaccine Immunotherapy Business (2018-2023) & (US\$ Million)
- Table 109. Northwest Biotherapeutics Recent Developments
- Table 110. Pique Therapeutics Company Details
- Table 111. Pique Therapeutics Business Overview
- Table 112. Pique Therapeutics Dendritic Cell Cancer Vaccine Immunotherapy Product
- Table 113. Pique Therapeutics Revenue in Dendritic Cell Cancer Vaccine Immunotherapy Business (2018-2023) & (US\$ Million)
- Table 114. Pique Therapeutics Recent Developments
- Table 115. Regeneus Company Details
- Table 116. Regeneus Business Overview
- Table 117. Regeneus Dendritic Cell Cancer Vaccine Immunotherapy Product
- Table 118. Regeneus Revenue in Dendritic Cell Cancer Vaccine Immunotherapy Business (2018-2023) & (US\$ Million)
- Table 119. Regeneus Recent Developments
- Table 120. Tessa Therapeutics Company Details
- Table 121. Tessa Therapeutics Business Overview

Table 122. Tessa Therapeutics Dendritic Cell Cancer Vaccine Immunotherapy Product

Table 123. Tessa Therapeutics Revenue in Dendritic Cell Cancer Vaccine Immunotherapy Business (2018-2023) & (US\$ Million)

Table 124. Tessa Therapeutics Recent Developments

Table 125. Vaccinogen Company Details

Table 126. Vaccinogen Business Overview

Table 127. Vaccinogen Dendritic Cell Cancer Vaccine Immunotherapy Product

Table 128. Vaccinogen Revenue in Dendritic Cell Cancer Vaccine Immunotherapy Business (2018-2023) & (US\$ Million)

Table 129. Vaccinogen Recent Developments

Table 130. XEME Biopharma Company Details

Table 131. XEME Biopharma Business Overview

Table 132. XEME Biopharma Dendritic Cell Cancer Vaccine Immunotherapy Product

Table 133. XEME Biopharma Revenue in Dendritic Cell Cancer Vaccine Immunotherapy Business (2018-2023) & (US\$ Million)

Table 134. XEME Biopharma Recent Developments

Table 135. Research Programs/Design for This Report

Table 136. Key Data Information from Secondary Sources

Table 137. Key Data Information from Primary Sources

List Of Figures

LIST OF FIGURES

Figure 1. Global Dendritic Cell Cancer Vaccine Immunotherapy Market Size Growth Rate by Type, 2018 VS 2022 VS 2029 (US\$ Million)

Figure 2. Global Dendritic Cell Cancer Vaccine Immunotherapy Market Share by Type: 2022 VS 2029

Figure 3. Provenge Features

Figure 4. Apceden Features

Figure 5. CreaVax Features

Figure 6. Others Features

Figure 7. Global Dendritic Cell Cancer Vaccine Immunotherapy Market Size Growth Rate by Application, 2018 VS 2022 VS 2029 (US\$ Million)

Figure 8. Global Dendritic Cell Cancer Vaccine Immunotherapy Market Share by Application: 2022 VS 2029

Figure 9. Pediatrics Case Studies

Figure 10. Adults Case Studies

Figure 11. Dendritic Cell Cancer Vaccine Immunotherapy Report Years Considered

Figure 12. Global Dendritic Cell Cancer Vaccine Immunotherapy Market Size (US\$ Million), Year-over-Year: 2018-2029

Figure 13. Global Dendritic Cell Cancer Vaccine Immunotherapy Market Size, (US\$ Million), 2018 VS 2022 VS 2029

Figure 14. Global Dendritic Cell Cancer Vaccine Immunotherapy Market Share by Region: 2022 VS 2029

Figure 15. Global Dendritic Cell Cancer Vaccine Immunotherapy Market Share by Players in 2022

Figure 16. Global Top Dendritic Cell Cancer Vaccine Immunotherapy Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Dendritic Cell Cancer Vaccine Immunotherapy as of 2022)

Figure 17. The Top 10 and 5 Players Market Share by Dendritic Cell Cancer Vaccine Immunotherapy Revenue in 2022

Figure 18. North America Dendritic Cell Cancer Vaccine Immunotherapy Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 19. North America Dendritic Cell Cancer Vaccine Immunotherapy Market Share by Type (2018-2029)

Figure 20. North America Dendritic Cell Cancer Vaccine Immunotherapy Market Share by Application (2018-2029)

Figure 21. North America Dendritic Cell Cancer Vaccine Immunotherapy Market Share

by Country (2018-2029)

Figure 22. United States Dendritic Cell Cancer Vaccine Immunotherapy Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 23. Canada Dendritic Cell Cancer Vaccine Immunotherapy Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 24. Europe Dendritic Cell Cancer Vaccine Immunotherapy Market Size YoY (2018-2029) & (US\$ Million)

Figure 25. Europe Dendritic Cell Cancer Vaccine Immunotherapy Market Share by Type (2018-2029)

Figure 26. Europe Dendritic Cell Cancer Vaccine Immunotherapy Market Share by Application (2018-2029)

Figure 27. Europe Dendritic Cell Cancer Vaccine Immunotherapy Market Share by Country (2018-2029)

Figure 28. Germany Dendritic Cell Cancer Vaccine Immunotherapy Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 29. France Dendritic Cell Cancer Vaccine Immunotherapy Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 30. U.K. Dendritic Cell Cancer Vaccine Immunotherapy Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 31. Italy Dendritic Cell Cancer Vaccine Immunotherapy Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 32. Russia Dendritic Cell Cancer Vaccine Immunotherapy Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 33. Nordic Countries Dendritic Cell Cancer Vaccine Immunotherapy Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 34. China Dendritic Cell Cancer Vaccine Immunotherapy Market Size YoY (2018-2029) & (US\$ Million)

Figure 35. China Dendritic Cell Cancer Vaccine Immunotherapy Market Share by Type (2018-2029)

Figure 36. China Dendritic Cell Cancer Vaccine Immunotherapy Market Share by Application (2018-2029)

Figure 37. Asia Dendritic Cell Cancer Vaccine Immunotherapy Market Size YoY (2018-2029) & (US\$ Million)

Figure 38. Asia Dendritic Cell Cancer Vaccine Immunotherapy Market Share by Type (2018-2029)

Figure 39. Asia Dendritic Cell Cancer Vaccine Immunotherapy Market Share by Application (2018-2029)

Figure 40. Asia Dendritic Cell Cancer Vaccine Immunotherapy Market Share by Region (2018-2029)

Figure 41. Japan Dendritic Cell Cancer Vaccine Immunotherapy Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 42. South Korea Dendritic Cell Cancer Vaccine Immunotherapy Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 43. China Taiwan Dendritic Cell Cancer Vaccine Immunotherapy Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 44. Southeast Asia Dendritic Cell Cancer Vaccine Immunotherapy Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 45. India Dendritic Cell Cancer Vaccine Immunotherapy Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 46. Australia Dendritic Cell Cancer Vaccine Immunotherapy Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 47. Middle East, Africa, and Latin America Dendritic Cell Cancer Vaccine Immunotherapy Market Size YoY (2018-2029) & (US\$ Million)

Figure 48. Middle East, Africa, and Latin America Dendritic Cell Cancer Vaccine Immunotherapy Market Share by Type (2018-2029)

Figure 49. Middle East, Africa, and Latin America Dendritic Cell Cancer Vaccine Immunotherapy Market Share by Application (2018-2029)

Figure 50. Middle East, Africa, and Latin America Dendritic Cell Cancer Vaccine Immunotherapy Market Share by Country (2018-2029)

Figure 51. Brazil Dendritic Cell Cancer Vaccine Immunotherapy Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 52. Mexico Dendritic Cell Cancer Vaccine Immunotherapy Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 53. Turkey Dendritic Cell Cancer Vaccine Immunotherapy Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 54. Saudi Arabia Dendritic Cell Cancer Vaccine Immunotherapy Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 55. Israel Dendritic Cell Cancer Vaccine Immunotherapy Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 56. GCC Countries Dendritic Cell Cancer Vaccine Immunotherapy Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 57. Lineage Cell Therapeutics Revenue Growth Rate in Dendritic Cell Cancer Vaccine Immunotherapy Business (2018-2023)

Figure 58. AVAX Technologies Revenue Growth Rate in Dendritic Cell Cancer Vaccine Immunotherapy Business (2018-2023)

Figure 59. DCPrime Revenue Growth Rate in Dendritic Cell Cancer Vaccine Immunotherapy Business (2018-2023)

Figure 60. Gradalis Revenue Growth Rate in Dendritic Cell Cancer Vaccine

Immunotherapy Business (2018-2023)

Figure 61. Heat Biologics Revenue Growth Rate in Dendritic Cell Cancer Vaccine

Immunotherapy Business (2018-2023)

Figure 62. ImmunoCellular Therapeutics Revenue Growth Rate in Dendritic Cell Cancer

Vaccine Immunotherapy Business (2018-2023)

Figure 63. Immunicum Revenue Growth Rate in Dendritic Cell Cancer Vaccine

Immunotherapy Business (2018-2023)

Figure 64. MolecuVax Revenue Growth Rate in Dendritic Cell Cancer Vaccine

Immunotherapy Business (2018-2023)

Figure 65. Northwest Biotherapeutics Revenue Growth Rate in Dendritic Cell Cancer

Vaccine Immunotherapy Business (2018-2023)

Figure 66. Pique Therapeutics Revenue Growth Rate in Dendritic Cell Cancer Vaccine

Immunotherapy Business (2018-2023)

Figure 67. Regeneus Revenue Growth Rate in Dendritic Cell Cancer Vaccine

Immunotherapy Business (2018-2023)

Figure 68. Tessa Therapeutics Revenue Growth Rate in Dendritic Cell Cancer Vaccine

Immunotherapy Business (2018-2023)

Figure 69. Vaccinogen Revenue Growth Rate in Dendritic Cell Cancer Vaccine

Immunotherapy Business (2018-2023)

Figure 70. XEME Biopharma Revenue Growth Rate in Dendritic Cell Cancer Vaccine

Immunotherapy Business (2018-2023)

Figure 71. Bottom-up and Top-down Approaches for This Report

Figure 72. Data Triangulation

Figure 73. Key Executives Interviewed

I would like to order

Product name: Global Dendritic Cell Cancer Vaccine Immunotherapy Market Insights, Forecast to 2029

Product link: <https://marketpublishers.com/r/GB6C5AE88D16EN.html>

Price: US\$ 4,900.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GB6C5AE88D16EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970